Ocera Therapeutics, Inc. (OCRX) Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research downgraded shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from a buy rating to a hold rating in a report released on Friday morning.
According to Zacks, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California. “
A number of other research firms have also commented on OCRX. HC Wainwright reaffirmed a buy rating and issued a $4.00 price objective on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Aegis reaffirmed a buy rating and issued a $3.00 price objective on shares of Ocera Therapeutics in a research note on Wednesday, May 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Ocera Therapeutics currently has an average rating of Buy and a consensus target price of $3.80.
Ocera Therapeutics (NASDAQ OCRX) opened at 0.95 on Friday. The firm’s market cap is $25.18 million. The stock has a 50 day moving average of $1.11 and a 200 day moving average of $1.10. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $3.15.
Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative return on equity of 175.02% and a negative net margin of 4,416.26%. Analysts anticipate that Ocera Therapeutics will post ($1.20) EPS for the current year.
WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/29/ocera-therapeutics-inc-ocrx-downgraded-by-zacks-investment-research-to-hold.html.
A number of large investors have recently modified their holdings of the company. Virtu KCG Holdings LLC increased its stake in shares of Ocera Therapeutics by 194.6% in the second quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 141,040 shares during the last quarter. Hikari Power Ltd increased its stake in shares of Ocera Therapeutics by 50.6% in the second quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 126,596 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Ocera Therapeutics during the first quarter worth $2,817,000. Finally, Renaissance Technologies LLC increased its stake in shares of Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares during the last quarter. Institutional investors and hedge funds own 20.25% of the company’s stock.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.